Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABRSLBF 93 EV-to-EBITDA is 23.35 as of Aug. 16, 2026, which is 24% below its 10-year median of 30.85. GuruFocus rates RSLBF with a GF Score™ of 93/100 and a GF Value™ of $18.11 (Fairly Valued). The stock has 2 warning signs investors should review. Among 511 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks worse than 81.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RaySearch Laboratories AB's enterprise value is $691.3 Mil.
RaySearch Laboratories AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $29.6 Mil. Therefore, RaySearch Laboratories AB's EV-to-EBITDA for today is 23.35.
The historical rank and industry rank for RaySearch Laboratories AB's EV-to-EBITDA or its related term are showing as below:
RSLBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4052.82 Med: 30.85 Max: 445.05
Current: 23.89
During the past 13 years, the highest EV-to-EBITDA of RaySearch Laboratories AB was 445.05. The lowest was -4052.82. And the median was 30.85.
RSLBF's EV-to-EBITDA is ranked worse than 81.41% of 511
companies
in the Healthcare Providers & Services industry
Industry Median: 10.69
vs RSLBF: 23.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
RaySearch Laboratories AB (OTCPK:RSLBF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RaySearch Laboratories AB's PE Ratio (TTM) for today is calculated as:
RaySearch Laboratories AB's share price for today is $18.85.
RaySearch Laboratories AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.664.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, RaySearch Laboratories AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's EV-to-EBITDA falls into.
RaySearch Laboratories AB's current Enterprise Value is $691.3 Mil.
RaySearch Laboratories AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $29.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (RSLBF) has a EV-to-EBITDA of 23.35 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RaySearch Laboratories AB. This is 24% below median its historical median of 30.85. According to the industry distribution chart, RaySearch Laboratories AB ranks #416 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 81.4%.
Is RaySearch Laboratories AB's EV-to-EBITDA too high?
RaySearch Laboratories AB's current EV-to-EBITDA of 23.35 is 24% below median its 10-year median of 30.85. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.69. RaySearch Laboratories AB's value of 23.35 is 118.4% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #416 out of 511 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #416 out of 511 companies for EV-to-EBITDA. This places RaySearch Laboratories AB in the lower half of its industry. The industry median EV-to-EBITDA is 10.69. RaySearch Laboratories AB's value of 23.35 is 118.4% above this benchmark. While the company's 10-year median is 30.85 vs. the industry median of 10.69, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.69, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current EV-to-EBITDA of 23.35 is 118.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RaySearch Laboratories AB. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current EV-to-EBITDA is 23.35, which is 24% below median its own 10-year median of 30.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (RSLBF) is currently considered Fairly Valued. The stock's GF Value™ is $18.11, compared to a current price of $18.85 — trading 4.1% above its estimated fair value. The current EV-to-EBITDA is 23.35, which is 24% below median its 10-year median of 30.85 and 118.4% above the Healthcare Providers & Services industry median of 10.69. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For RaySearch Laboratories AB (RSLBF), the current EV-to-EBITDA is 23.35 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (RSLBF) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of $18.85 is trading 4.1% above its estimated GF Value™ of $18.11.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for RSLBF:
EV-to-EBITDA: 23.35 (24% below median its 10-year median of 30.85)
GF Value™: $18.11 vs. price of $18.85 (4.1% above fair value)
Industry Position: 118.4% above the Healthcare Providers & Services median (#416 of 511)
No single metric tells the full story. See the RSLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for RSLBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSLBF has been successfully added to your 
